Jane Street’s Clearside Biomedical CLSD Stock Holding History

Jane Street’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,653	Closed	-$149K	–	10131
2021 Q3	$149K	Buy	+1,653	New	+$146K	﹤0.01%	9066

Other funds holding CLSD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GGH

GCM Grosvenor Holdings Chicago, Illinois $901M AUM 28.6% 1-Year Est. Return

Jane Street's CLSD Position: Q3 2024 in Review

Jane Street sold out of Clearside Biomedical (CLSD) in Q3 2024, closing a stake of 1,913 shares — an estimated $37.3K sold.

Jane Street first reported a position in CLSD in Q2 2019 and held it in 9 quarters. The position peaked at $270K in Q1 2024. 48 funds tracked by Wall St. Rank hold CLSD as of Q3 2024.

Jane Street reported no remaining Clearside Biomedical position as of Q3 2024 after selling out during the quarter.
Jane Street sold 1,913 Clearside Biomedical shares in Q3 2024, an estimated $37.3K.
Jane Street first reported a position in Clearside Biomedical in Q2 2019 and held it in 9 quarters.
Jane Street's Clearside Biomedical position peaked at $270K in Q1 2024.
48 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2024.

Based on Jane Street's 13F filing for Q3 2024, filed 15 Nov 2024.